New findings published in the Lancet (2023;401:269-280) suggest momelotinib (GSK) can be a valuable addition to the armamentarium for the treatment of anemic patients with myelofibrosis. The phase 3 study results showed that the agent was significantly more effective than danazol in improving myelofibrosis-associated symptoms as well as anemia and spleen response.
“The clinical benefit seen with momelotinib in patients with myelofibrosis and anaemia, including the reduction of transfusion